Pharmaceuticals Form D filings.
83 Form D notices were filed in the Pharmaceuticals industry group in Q2 2026 and Q3 2026, 68 new and 15 amendments. 96.4% claimed Rule 506(b) and 3.6% Rule 506(c).
- Notices
- 83
- Amendments
- 15
- Rule 506(c)
- 3.6%
- Pooled funds
- 0.0%
- Amount sold, new notices
- $449.9M
- Latest filing
- 2026-09-28
Latest notices
| Filed | Issuer | Location | Type | Amount sold | Offering size | Exemptions |
|---|---|---|---|---|---|---|
| 2026-09-28 | Laurentide Therapeutics Inc. | Georgia | D | $100K | $100K | Rule 506(b) |
| 2026-09-25 | Dignify Therapeutics, LLC | North Carolina | D | $800K | $3.0M | Rule 506(b) |
| 2026-09-22 | Pierrepont Therapeutics, Inc. | New York | D/A | $2.4M | $5.9M | Rule 506(b) |
| 2026-09-18 | Aqur Biosciences, Inc. | California | D | $1.5M | $1.5M | Rule 506(b) |
| 2026-09-17 | IMACS Working Capital Facility One LLC | Michigan | D | $200K | $5.0M | Rule 506(b) |
| 2026-09-16 | FibroBiologics, Inc. | Texas | D | $500K | $500K | Rule 506(b) |
| 2026-09-10 | Can-Fite BioPharma Ltd. | Israel | D | $8.3M | $8.3M | Rule 506(b) |
| 2026-09-10 | Quoin Pharmaceuticals Ltd. | Virginia | D | $50.0M | $50.0M | Rule 506(b) |
| 2026-09-04 | Immunophotonics, Inc. | Missouri | D | $10.1M | Indefinite | Rule 506(b) |
| 2026-09-03 | Inventure, LLC | Connecticut | D | $82K | $82K | Rule 506(b) |
| 2026-09-02 | Telemachus Therapeutics, Inc. | Pennsylvania | D | $125K | $1.5M | Rule 506(b) |
| 2026-08-28 | DalCor Pharmaceuticals US, LLC | Florida | D | $7.0M | $7.0M | Rule 506(b) |
| 2026-08-27 | Eos SENOLYTIX, Inc. | Texas | D/A | $750K | $25.0M | Rule 506(b) |
| 2026-08-26 | Aptevo Therapeutics Inc. | Washington | D | $3.5M | $3.5M | Rule 506(c) |
| 2026-08-20 | LifeCyte Innovations, Inc. | Georgia | D | $1.0M | $5.0M | Rule 506(b) |
| 2026-08-20 | Sentonix, Inc. | Massachusetts | D | $12.7M | $21.2M | Rule 506(b) |
| 2026-08-19 | Intercure Ltd. | Israel | D | $0 | Indefinite | Rule 506(b) |
| 2026-08-14 | MBQ PHARMA INC. | Puerto Rico | D | $991K | Indefinite | Rule 506(b) |
| 2026-08-14 | MBQ PHARMA INC. | Puerto Rico | D | $500K | $500K | Rule 506(b) |
| 2026-08-14 | MBQ PHARMA INC. | Puerto Rico | D | $325K | $325K | Rule 506(b) |
| 2026-08-14 | MBQ PHARMA INC. | Puerto Rico | D | $882K | $882K | Rule 506(b) |
| 2026-08-14 | MBQ PHARMA INC. | Puerto Rico | D | $1.5M | Indefinite | Rule 506(b) |
| 2026-08-14 | Maxona Pharmaceuticals, Inc. | Pennsylvania | D/A | $5.8M | $12.0M | Rule 506(b) |
| 2026-08-12 | BTB Therapeutics, Inc. | California | D/A | $8.9M | $10.4M | Rule 506(b) |
| 2026-08-11 | ELLA LEROY Corp | Hawaii | D | $50K | $75K | Rule 506(b) |
| 2026-08-11 | Grace Therapeutics, Inc. | New Jersey | D | $10.0M | $10.0M | Rule 506(b) |
| 2026-08-10 | PLEOPHARMA, INC. | Pennsylvania | D | $5.5M | $15.0M | Rule 506(b) |
| 2026-08-07 | Duo Oncology Inc. | Pennsylvania | D/A | $1.6M | $3.5M | Rule 506(b) |
| 2026-08-06 | InnovoTEX Inc. | Texas | D | $750K | $4.0M | Rule 506(b) |
| 2026-08-06 | Cerium Pharmaceuticals, Inc. | Maryland | D | $750K | $2.5M | Rule 506(b) |
Median minimum investment accepted, among the 9 notices above that report one: $50,000.
Query these notices
The Form D offerings endpoint returns every notice for a quarter with all issuer identities and source strings. Filter by issuer CIK, or page through a quarter and group by industry or location yourself.
curl "https://sec-api.dev/api/v1/offerings?period=2026q3&limit=25" \
-H "Authorization: Bearer $SEC_API_KEY"Questions
How many Form D filings were in Pharmaceuticals?
83 Form D notices were filed in the Pharmaceuticals industry group in Q2 2026 and Q3 2026, 68 new and 15 amendments. 96.4% claimed Rule 506(b) and 3.6% Rule 506(c).
Does amount sold equal money raised this quarter?
No. The total amount sold on a notice is cumulative for the offering. Use new notices, or the latest amendment per offering, to avoid double counting.
Other industries
Plain-text version for agents and LLMs: /form-d/industries/pharmaceuticals.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.